Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma | MicrobiomeTrials← Back to trialsNCT07502287
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-03-02Est. Completion: 2027-03-14
Enrollment target: 36 participants Locations- Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Other microbiome trials you might be interested in
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaEwing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United StatesEst. completion Mar 31, 2029
Malignant Neoplasm
Researchers are looking for new ways to treat children with relapsed or refractory solid tumors:
* Relapsed means the c…
Aurora, United States
Est. completion Aug 17, 2031
MedulloblastomaCentral Nervous System Embryonal TumorRefractory MedulloblastomaRecurrent MedulloblastomaPediatric Brain TumorEmbryonal Tumor With Multilayered Rosettes (ETMR)PineoblastomaAtypical Teratoid/Rhabdoid Tumor (ATRT) of the CNSCNS NeuroblastomaFOXR2-activated
This is a single-site, open-label Phase I treatment study evaluating the manufacturing feasibility and safety of chimeri…
Palo Alto, United StatesEst. completion Aug 2027